ROLE OF NEUROHUMORAL ACTIVATION IN THE DEVELOPMENT OF HYPERTENSION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Download full text PDF
Issue: 
2
Year: 
2015

E. Selezneva, Professor T. Zhdanova, MD Ural State Medical University, Yekaterinburg

Chronic obstructive pulmonary disease is presently considered as a disease of the airways and lung with systemic manifestations. The latter include cardiovascular events, particularly hypertension that may be caused by hypoxemia, systemic inflammation, systemic oxidative stress, and neurohumoral activation.

Keywords: 
chronic obstructive pulmonary disease
neurohumoral activation
hypertension



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Sin D., Wu L., Man S. The relationship between reduced lung function and 1. cardiovascular mortality: A population-based study and a systematic review of theliterature // Chest. – 2005; 127 (6): 1952–9.
  2. World Health Organization. Constitution of the World Health Organization. 2. 2006. http //apps.who.int/gb/bd/PDF/bd47/EN/constitution-en.pdf
  3. Cazzola M., Puxeddu E., Bettoncelli G. et al. The prevalence of asthma and 3. COPD in Italy: a practice-based study // Respir. Med. – 2011; 105: 386–91.
  4. Oganov R.G., Timofeeva T.N., Koltunov I.E. i dr. Epidemiologija arte-4. rial'noj gipertonii v Rossii. Rezul'taty Federal'nogo monitoringa 2003–2010gg. // Kardiovaskuljarnaja terapija i profilaktika. – 2011; 1: 9–13.
  5. Curkendall S., DeLuise C., Jones J. et al. Cardiovascular disease in patients 5. with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients // Ann. Epidemiol. – 2006; 16: 63–70.
  6. Fabbri L., Luppi F., Beghe B. et al. Complex chronic comorbidities of COPD 6. // Eur. Respir. J. – 2008; 31: 204–12.
  7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for 7. thediagnosis, management and prevention of chronic obstructive pulmonary disease.NHLBI // WHO workshop repot Updated 2013. www.goldcopd.com
  8. Steckelings U., Unger T. The renin–angiotensin–aldosterone system; in 8. Mancia G, Grassi G, Kjeldsen S. Manual of Hypertension of The European Society of Hypertension // Abingdon, Informa HealthCare. – 2008; 14: 110–6.
  9. Gan W., Man S., Senthilselvan A. et al. The association between chronic 9. obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis // Thorax. – 2004; 59: 574–80.
  10. Touyz R. Reactive oxygen species in vascular biology: role in arterial 10. hypertension // Expert Rev. Cardiovasc. Ther. – 2003; 1: 91–106.
  11. Lemarie C., Esposito B., Tedgui A. et al. Pressure-induced vascularactivation 11. of nuclear factor-kappaB: role in cell survival // Circ. Res. – 2003; 93: 207–12.
  12. Venugopal S., Devaraj S., Jialal I. Effect of C-reactive protein on vascularcells: 12. evidence for a proinflammatory, proatherogenic role // Curr. Opin. Nephrol. Hypertens. – 2005; 14: 33–7.
  13. Bellocchia M., Masoero M., Ciuffreda A. Predictors of cardiovascular 13. disease in asthma and chronic obstructive pulmonary disease. Turin, Italy Multidisciplinary Respiratory Medicine, 2013.